Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2019 Oct 7;367:l5460. doi: 10.1136/bmj.l5460

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions

This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/.

PMC Copyright notice

Fig 6 — Bayesian ranking profiles of comparable treatments on safety for patients with advanced epidermal growth factor receptor mutated, non-small cell lung cancer, stratified into exon 19 deletion and Leu858Arg subgroups. Profiles indicate the probability of each comparable treatment being ranked from first to last on progression free survival and overall survival. Ranking curves are described according to the bayesian ranking results presented in supplementary table S3. Osi=osimertinib; Dac=dacomitinib; Afa=afatinib; Erl=erlotinib; Gef=gefitinib; Ico=icotinib; Bev=bevacizumab; Gef+P=gefitinib plus pemetrexed; PbCT=pemetrexed based chemotherapy; PfCT=pemetrexed free chemotherapy